Investigation Launched into Sionna Therapeutics over Mixed Clinical Trial Results

NEW YORK, Sept. 3, 2026 /CourierPR/ -- Pomerantz Law Firm Launches Investigation into Sionna Therapeutics, Inc.

Investors in Sionna Therapeutics, Inc. (NASDAQ: SION) are advised to contact the law firm of Pomerantz LLP regarding potential securities fraud claims. The investigation stems from a press release issued by Sionna on August 10, 2026, which detailed mixed results from its clinical trials for NBD1 stabilizers.

According to the press release, Sionna reported positive outcomes from two of its nucleotide binding domain 1 (NBD1) stabilizer programs: the PreciSION CF Phase 2a proof-of-concept (POC) trial of SION-719 when added to Trikafta® (elexacaftor/tezacaftor/ivacaftor) in cystic fibrosis (CF) participants, and the Phase 1 trial of SION-451-based proprietary dual combinations in healthy subjects. However, the PreciSION CF trial failed to meet its primary endpoint, which was to measure the reduction in sweat chloride when SION-719 was administered alongside the standard-of-care treatment Trikafta.

Following this news, Sionna's stock price plummeted, closing at $4.50 per share, down 91.18% from its previous level of $46.54 per share on the same day.

Pomerantz LLP, headquartered in New York with offices in Chicago, Los Angeles, London, Paris, and Tel Aviv, has a long history of pioneering securities class litigation. Founded by Abraham L. Pomerantz, the firm has a reputation for representing victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm has secured numerous multimillion-dollar damage awards for its clients.

Pomerantz LLP is a leader in corporate, securities, and antitrust class litigation, and the firm's commitment to justice for its clients remains unwavering.